Revolution Medicines Reports Third Quarter 2026 Financial Results and Update on Corporate Progress
Revolution Medicines, Inc. (RVMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Revolution Medicines Reports Third Quarter 2026 Financial Results and Update on Corporate Progress · Received U.S. FDA approval and launched RASONQUE® (daraxonrasib) for adult patients with metastatic pancreatic cancer who have received at least one prior systemic th
How this was made
The 30-second read
Why it matters
The approval creates a new revenue stream and validates the company's RAS‑ON platform, likely driving short‑term buying interest.
Market read
First‑report FDA approval and launch provide fresh, material information for traders; the stock is expected to react positively.
What to watch
Reimbursement negotiations and pricing in Europe could delay commercial upside beyond the U.S. launch.
Revolution Medicines Reports Third Quarter 2026 Financial Results and Update on Corporate Progress
The first partial quarter of RASONQUE sales generated $197.6 million of net product revenue following U.S. approval and launch, but the company reported a $407.5 million net loss amid substantial development and commercialization spending. Management emphasized that early-launch revenue included finite Expanded Access Program transitions, a cohort of waiting patients and channel inventory stocking.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Product revenue, net, three months ended September 30GAAP | $197.6M | – | – |
| Cost of sales, three months ended September 30GAAP | 327 | – | – |
| Research and development, three months ended September 30GAAP | 417,087 | – | – |
| Selling, general and administrative, three months ended September 30GAAP | 153,294 | – | – |
| Total costs and expenses, three months ended September 30GAAP | 570,708 | – | – |
| Loss from operations, three months ended September 30GAAP | (373,149) | – | – |
| Interest income, three months ended September 30GAAP | 37,779 | – | – |
| Interest expense, three months ended September 30GAAP | (33,804) | – | – |
| Change in fair value of warrant liability, three months ended September 30GAAP | (40,702) | – | – |
| Other income (expense), net, three months ended September 30GAAP | 66 | – | – |
| Total non-operating income (expense), net, three months ended September 30GAAP | (36,661) | – | – |
| Loss before income taxes, three months ended September 30GAAP | (409,810) | – | – |
| Benefit from income taxes, three months ended September 30GAAP | 2,353 | – | – |
| Net loss, three months ended September 30GAAP | −$407.5M | – | – |
| Net loss per share, basic and diluted, three months ended September 30GAAP | $ (1.90) | – | – |
| Weighted-average common shares used to compute net loss per share, basic and diluted, three months ended September 30GAAP | 214,946,012 | – | – |
| Product revenue, net, nine months ended September 30GAAP | $197.6M | – | – |
| Cost of sales, nine months ended September 30GAAP | 327 | – | – |
| Research and development, nine months ended September 30GAAP | 1,155,976 | – | – |
| Selling, general and administrative, nine months ended September 30GAAP | 364,759 | – | – |
| Total costs and expenses, nine months ended September 30GAAP | 1,521,062 | – | – |
| Loss from operations, nine months ended September 30GAAP | (1,323,503) | – | – |
| Interest income, nine months ended September 30GAAP | 92,866 | – | – |
| Interest expense, nine months ended September 30GAAP | (69,782) | – | – |
| Change in fair value of warrant liability, nine months ended September 30GAAP | (207,521) | – | – |
| Other income (expense), net, nine months ended September 30GAAP | (57) | – | – |
| Total non-operating income (expense), net, nine months ended September 30GAAP | (184,494) | – | – |
| Loss before income taxes, nine months ended September 30GAAP | (1,507,997) | – | – |
| Benefit from income taxes, nine months ended September 30GAAP | 2,353 | – | – |
| Net loss, nine months ended September 30GAAP | −$1.51B | – | – |
| Net loss per share, basic and diluted, nine months ended September 30GAAP | $ (7.24) | – | – |
| Weighted-average common shares used to compute net loss per share, basic and diluted, nine months ended September 30GAAP | 208,040,935 | – | – |
| Cash, cash equivalents and marketable securities, September 30GAAP | $3.65B | – | – |
| Working capital, September 30other | 3,501,031 | – | – |
| Total assets, September 30GAAP | 4,303,514 | – | – |
| Total liabilities, September 30GAAP | 1,902,011 | – | – |
| Total stockholders' equity, September 30GAAP | 2,401,503 | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| RASONQUE (daraxonrasib)Approximately five weeks of commercial availability following U.S. FDA approval on August 26, 2026, including patients transitioning from the U.S. Expanded Access Program, patients awaiting an approved treatment option, newly eligible patients and initial stocking of inventory into the channel. | $197.6M | – | – |
full-year 2026 outlook
- Operating expenses$2.1 billion to $2.2 billion
- NoteExpected non-cash stock-based compensation expense of $270 million to $290 million.
What drove it
- The U.S. FDA approved RASONQUE on August 26, 2026, and the company immediately launched the product in the U.S.
- More than 5,000 unique patients received commercial RASONQUE in the U.S. from FDA approval through September 30, 2026.
- RASONQUE claims have been reimbursed across health plans collectively representing greater than 90% of U.S. PDAC covered lives while formal coverage policies continue to develop.
- Research and development expense increased primarily because of higher clinical trial and manufacturing expenses for RASONQUE, zoldonrasib and RMC-5127, additional headcount and higher stock-based compensation expense.
- Selling, general and administrative expense increased primarily because of additional headcount, RASONQUE commercial-launch expenses and higher stock-based compensation expense.
- Cost of sales was not representative of normalized cost of sales because product sold during the quarter included inventory manufactured before FDA approval for which manufacturing costs were previously expensed to research and development.
Concerns
- The company stated that the Expanded Access Program transition and initial cohort of waiting patients are finite early-launch dynamics and that third-quarter results should not be viewed as indicative of RASONQUE's longer-term trajectory.
- The company reported a net loss of $407.5 million for the quarter ended September 30, 2026.
- Net loss for the quarter included non-cash charges of $40.7 million related to a change in the fair value of warrants assumed as part of the acquisition of EQRx, Inc.
- A decision by the European Commission on the marketing application for RASONQUE is pending, and commercial availability following potential approval will vary by country.
What to watch
- European Commission decision on the marketing application for RASONQUE following the positive CHMP opinion.
- Global enrollment completion in RASolute 303, expected in the first half of 2027.
- Closure of enrollment at all RASolve 301 sites by the end of November 2026 and the anticipated initial readout in 2027.
- Clinical data update from earlier-phase colorectal cancer studies and the RASonate 312 trial design in the first half of 2027.
- Initial clinical monotherapy data for RMC-5127 in 2027.
- Initiation of a first-in-human clinical trial of RM-055 in the fourth quarter of 2026.
Balance sheet and cash flow
- Cash, cash equivalents and marketable securities were $3.7 billion as of September 30, 2026.
- The September 30, 2026 cash, cash equivalents and marketable securities balance excludes $250 million in proceeds received in October associated with the first mandatory debt tranche under the Royalty Pharma funding arrangement.
- RASONQUE’s U.S. approval triggered the mandatory first debt tranche of $250 million under the Royalty Pharma funding arrangement.
- The company elected not to draw the optional third royalty financing tranche of $250 million.
- Up to an additional $1 billion in committed capital remains available under the funding arrangement, subject to achievement of specified milestones.
Analysis
Revolution Medicines entered a commercial stage during the third quarter with the August 26, 2026 U.S. approval and immediate launch of RASONQUE. RASONQUE generated $197.6 million of net product revenue during approximately five weeks of commercial availability. The launch reached more than 5,000 unique U.S. patients from approval through September 30, 2026, and claims have been reimbursed across health plans representing greater than 90% of U.S. PDAC covered lives. The company also cited its inclusion in NCCN Guidelines as a Category 1 Preferred subsequent-therapy option for appropriate pancreatic cancer patients.
The initial revenue figure has unusual launch-period composition. Management said it included patients transitioning from the Expanded Access Program, patients who had exhausted available options while awaiting approval, newly eligible patients and initial channel inventory stocking. It specifically identified the Expanded Access transition and initial waiting cohort as finite early-launch dynamics and said third-quarter results should not be viewed as indicative of the launch's longer-term trajectory. Cost of sales was $0.3 million, but the company said it was not representative of normalized cost of sales because manufacturing costs for product sold had previously been expensed to research and development.
Investment remained elevated across both development and commercialization. Research and development expense was $417.1 million, compared with $262.5 million in the prior-year quarter, driven by clinical trial and manufacturing expenses for RASONQUE, zoldonrasib and RMC-5127, additional headcount and stock-based compensation. Selling, general and administrative expense was $153.3 million, compared with $52.8 million, reflecting headcount, commercial-launch costs and stock-based compensation. The resulting net loss was $407.5 million, compared with a net loss of $305.2 million, and included a $40.7 million non-cash warrant fair-value charge.
Liquidity stood at $3.7 billion of cash, cash equivalents and marketable securities as of September 30, 2026, excluding $250 million received in October from the mandatory first Royalty Pharma debt tranche. The company did not draw the optional $250 million third royalty tranche and said up to an additional $1 billion remains available, subject to specified milestones. Management reiterated full-year 2026 GAAP operating expense guidance of $2.1 billion to $2.2 billion, including expected non-cash stock-based compensation expense of $270 million to $290 million. The next operational milestones include the pending European Commission decision, completion of RASolute 303 enrollment in the first half of 2027 and an anticipated initial RASolve 301 readout in 2027.
Management, verbatim
The U.S. approval and launch of RASONQUE marked a monumental step forward for eligible patients with pancreatic cancer and a transformational quarter for Revolution Medicines, and the CHMP opinion sets the stage for potential approval in the European Union.
Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines
Not in the filing
stated, not guessed- GAAP gross margin
- Non-GAAP revenue, earnings, operating income or EPS measures
- Prior-quarter comparisons for reported operating metrics
- Reported year-over-year percentage changes for reported operating metrics
- Operating cash flow
- Free cash flow
- Debt balance as of September 30, 2026
- Share repurchases
- Dividends
- Full-year 2026 revenue guidance
- Full-year 2026 gross-margin guidance
- Full-year 2026 tax-rate guidance
- Previous-release outlook for comparison with actual results
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was checked against the filing text, and a metric whose value, prior period and change do not add up is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Revolution Medicines filed a Form 8‑K announcing Q3 2026 results, FDA approval of RASONQUE for metastatic pancreatic cancer, and a positive CHMP opinion for EU approval.
Ticker impact
SEC 8‑K reports FDA approval and U.S. launch of RASONQUE, generating $198 million net revenue in Q3 2026.
likely upward pressure as the market prices in the new product revenue.
First‑report FDA approval for a commercial‑stage oncology drug, with immediate sales and CHMP opinion, is material for a biotech.
Market effects
Ras‑targeted oncology may see increased investor interest, benefiting peers in the cancer‑drug space.
U.S. biotech sector could see a modest boost as a new FDA‑approved therapy adds to pipeline depth.
Positive CHMP opinion signals potential future EU launch, supporting broader biotech sentiment.
Counterpoint
If launch uptake slows after the initial access‑program patients, revenue may fall short of expectations.
Key entities
- companyRevolution Medicines, Inc.
Biotech firm developing RAS‑ON inhibitors.
- productRASONQUE (daraxonrasib)
Oral RAS‑ON inhibitor approved for metastatic pancreatic cancer.
